cytomed – cytomed

CytoMed's Technologies

CytoMed is translating its patent-pending technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based "off-the-shelf"
immunotherapeutics for a wide range of cancers.

CytoMed also engages in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using
our proprietary technologies for our customers.

#01

iPSC-γδ NKT Cell Technology
(gdNKT Therapy)

#02

CAR-γδ T Cell Technology
(CTM-N2D Therapy)

CytoMed Therapeutics

Incorporated in 2018, CytoMed Therapeutics is a spin-off from Singapore’s Agency for Science, Technology and Research (A*Star) focused on engineering more affordable cellular cancer therapies to identify and attack a multitude of solid & hematological cancers.

Read More

Publications

View All Publications
Beta-2 Microglobulin Knockout K562 Cell-Based Artificial Antigen Presenting Cells For Ex Vivo Exp...

Chen C,Du Z,Li Z,Tay JC,Wang S,Zha S,

Immunotherapy 2019, 11: 967- 982

Chimeric Switch Receptor: Switching for Improved Adoptive T-Cell Therapy Against Cancers

Tay JC,Wang S,Zha S,

Immunotherapy 2017, 9: 1339- 1349

Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells

Wang S,Wu C,Zeng J,

Scientific Reports 2015, 5: 15262

Baculoviral Vector-Mediated Transient and Stable Transgene Expression in Human Embryonic Stem Cells

Du J,Palanisamy N,Wang S,Zeng J,Zhao Y,

Stem Cells 2009, 25: 1055- 1061